Winter 2021 Newsletter
Released Date: February 23, 2021
Happy New Year! I am humbled, honored and privileged to serve as the President of GASPEN for the next two years. I am excited to have Ashley Matthews (MS, RDB, LD, CNSC, PMP) to serve as the new president-elect and Laura Costlow (MA, RD, LD, CNSC) to serve as the new secretary-treasurer alongside with me. Thank you Khatija Jivani (PharmD), immediate past GASEPN president and the entire GASPEN board for laying the foundation for our chapter success. I want to thank all the GASPEN members for your continuous support through volunteering in our committees and participating in our educational programs and annual conference. As a chapter, we are ready to put 2020 behind us and pull together to make 2021 a better year.
I am thrilled to announce the upcoming joint meeting between SE SCCM and GASPEN on February 23rd, featuring Dr. Paul Wischmeyer. His presentation is “Nutrition and Metabolic Needs in COVID-19”. Hope you can join us on this virtual presentation. In addition, the GASPEN board has started to plan for our annual conference (Date TBD). We strive to improve our annual conference experience for members every year. Hence our GASPEN board members will be reviewing the post-meeting survey questions and answers from our first Virtual Conference that took place in November 13th, 2020. We welcome any suggestions and comments from GASPEN members for ways to make our conference more beneficial for our members. You can email us at GASPENGA@gmail.com.
For 2021, we are calling for volunteers to support a variety of GASPEN committees to help us grow as a chapter. We are planning to expand our newly launched GASPEN YouTube channel to provide variety of resources for members. We are hoping to launch a GASPEN website, where members access all information in one central place. If you are interested in volunteering as a committee member, please send an email to GASPENGA@gmail.com.
Thank you! I look forward to another wonderful year with GASPEN!
Vivian Zhao, PharmD, BCNSP
Injectable Lipid Emulsion Safety Review
Katie McCrory, PharmD
Although crucial for delivering essential fatty acids (EFAs), as well as energy to patients receiving parenteral nutrition (PN), use of injectable lipid emulsions (ILE) requires careful understanding of risks and appropriate use. The historical ILE formulation, solely comprised of soybean oil, has the benefit of being rich in EFAs, however, it is also considered highly pro-inflammatory and immunosuppressive due to a high omega (ω)-6 fatty acid content. This is particularly of concern in the critically ill population and has resulted in a recommendation from ASPEN/SCCM 2016 guidelines to withhold ILE therapy for the first week in critically ill, or limit use to 100 g per week, if at risk for development of essential fatty acid deficiency (EFAD), defined as a triene:tetrane ratio > 0.2. Given the concern over the inflammatory and immunosuppressive nature of the soybean-based ILE products (SO-ILE), new “generations” (Table 1) of ILE have recently been developed with a reduced soybean oil content, while still providing EFAs from other sources. With a decreased ω-6 fatty acid content and an improved ω-6:ω-3 ratio, these newer products may prove safe and effective for critically ill patients of note, the ASPEN/SCC 2016 guideline recommendations to withhold ILE therapy in the first week of critical illness were published before the approval of these newer agents in the United States.
See PDF for the full article.
Read the full Newsletter here: LINK